Featured Story | By Nick Paul Taylor Biotechs targeting the “don’t eat me” signal cancer cells use to avoid the immune system are getting gobbled up. Pfizer is the latest company to buy its way into the space, splashing out $2.3 billion to acquire Trillium Therapeutics for its early-phase inhibitors of the CD47 macrophage checkpoint. read more |
| |
|---|
|
|  | Dedicated AAV Gene Therapy Manufacturing Utilize our property technologies, including our royalty-free clonal HEK293 Ignition Cells™, and custom-designed smaller pEMBR™ helper plasmid with improved safety profile. With limited capacity remaining in 2021, accelerate your gene therapy program at any stage from preclinical through clinical, and onto commercial manufacturing. Forge ahead with us! |
Top Stories By Nick Paul Taylor David Sabatini, the scientific founder of several biotechs, has been ousted from his lab after a sexual harassment investigation. The high-profile cell signaling and cancer metabolism scientist is “no longer associated” with either the Whitehead Institute or the Howard Hughes Medical Institute. read more By Annalee Armstrong Anti-aging research group the SENS Research Foundation has fired chief science officer Aubrey de Grey, who was accused of sexual harassment by two women earlier this month. read more By Ben Adams A new depression therapy out from Axsome was expected to be handed a final FDA decision over the weekend, but the agency has nixed that, for now. read more By Ben Adams Just a few short months after getting off a $106 million funding round and beefing up its C-suite as it looks to tap its SNAP platform to fight resistance to cancer drugs, Tyra Biosciences has filed to raise $100 million in an IPO. read more By Ben Adams Forever biotech friend Takeda is signing up to a new deal with Genevant as it doubles down on the company. read more By Kyle LaHucik Elixiron is currently testing its lead asset, an oral CSF1R inhibitor, in healthy volunteers for safety and tolerability in a phase 1 trial. With the $27 million series A, the cancer and neurological diseases biotech looks to bring the asset into an Alzheimer's disease clinical trial, as well as test its antibody in vitiligo patients. read more By Eric Sagonowsky While much of the attention at the European Society of Cardiology is expected to center on forthcoming heart failure data for Eli Lilly and Boehringer Ingelheim’s Jardiance, Lexicon Pharmaceuticals thinks it has a winner in the dual SGLT1 and SGLT2 inhibitor sotagliflozin. read more By Arlene Weintraub Using CRISPR, a team at Penn’s medical school discovered that an epigenetic regulatory protein called ZMYND8 governs the expression of genes that are critical for the growth and survival of AML cells. They uncovered a way to target it with drugs and to predict which patients are likely to respond to ZMYND8 inhibition. read more By Conor Hale Drops in demand for COVID-19 screening have led test maker LumiraDx to dramatically cut back its plans for going public, slashing 40% off the value of a planned reverse merger. read more By Fraiser Kansteiner Drugmakers have myriad tools in their arsenal when looking to grow sales, but it's new drug approvals that reign supreme and ultimately prove the worth of a company's development engine. See how 11 of the world's top drugmakers are faring. read more By Heather Landi Google says it is ramping up its investments in health-focused initiatives even as it dissolves its single health division. One industry analyst says the move to shutter the dedicated health division signals the end of a unified healthcare strategy at Google. So what's next for the tech giant's healthcare operations? read more Resources Sponsored by: Patheon by Thermo Fisher Scientific Learn how a decentralized clinical trial strategy improves patient recruitment, reduces drop-out rates, and ultimately streamlines the path to the next trial phase. Sponsored by: Patheon by Thermo Fisher Scientific Learn how to build a robust packaging strategy and the key technical considerations in packaging design and operational planning to enable rapid commercialization of pharmaceuticals. Sponsored by: Patheon by Thermo Fisher Scientific Learn how regulations are changing and key considerations for commercializing cell and gene therapies without sacrificing quality. Sponsored By: LabVantage Solutions, Inc. Uncover the real impact of “digital transformation” with practical advice to help you plan your own transformative journey to a harmonized digital ecosystem. Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. | 
